Inflammation of seborrheic keratoses due to docetaxel treatment [11]
Journal
Acta Dermato-Venereologica
Journal Volume
81
Journal Issue
4
Pages
316-317
Date Issued
2001
Author(s)
Abstract
In December 1998, a 72-year-old woman was given a diagnosis of non-small-cell lung cancer. Previous treatment included left upper lobectomy with lymph node dissection followed by 4 cycles of chemotherapy with gemcitabine and cisplatin. Docetaxel was administered because of disease progression. The dosage schedule of each cycle was intravenous infusion of docetaxel for 30min on days 1, 8 and 15 and the dosage was 45mg/m2 weekly for each injection. However, severe leukopenia following the rst dose led to delayed administration of the second injection until day 19 after the rst injection. Four days after the second injection, some peato bean-sized, itching, erythematous macules and patches developed on the right forearm and dorsum of the right hand. All of these lesions corresponded to the sites of pre-existing seborrheic keratoses (Fig. 1). The patient claimed that the seborrheic keratoses had been noted for more than 10 years and there was no history of eruptive appearance of new seborrheic keratoses. The injection sites of docetaxel therapy were on the Fig. 1. Some peato bean-sized, itching, erythematous macules and left, rather than right, forearm. There was no extravasation patches with scales were noted on the right forearm and dorsum of event during the docetaxel treatment. A skin biopsy was not the right hand. All of these lesions corresponded to the sites of preundertaken, owing to leukopenia. The patient’s skin condition existing seborrheic keratoses. was treated as eczema, with betamethasone valerate cream. The second cycle of docetaxel infusion was still administered, with the dosage reduced to 36mg/m2 because of the leukopenia. The in ammation of seborrheic keratoses ameliorated Both of these reports describe a patient with acute myelogenous one week later, but the patient complained of a tingling and leukemia who had a rapidly increasing number of seborrheic burning sensation over the area. One month after the onset of keratoses, compatible with Leser-Trelat sign. Following the lesions, an erythematous, palm-sized plaque with sensory chemotherapy, the seborrheic keratoses of Leser-Trelat became change was noted on the right forearm, partly localized to the in amed in both patients; with discontinuation of cytarabine keratoses. Fixed erythrodysesthesia plaque (FEP) due to docetherapy, the in ammatory reaction in the keratoses subsided taxel was diagnosed (3). One month later, the skin lesions in one of the patients (5). All the seborrheic keratoses of our resolved, but the pre-existing seborrheic keratoses remained. patient had been present for more than 10 years, which made The same skin reaction did not recur even though the patient Leser-Trelat sign unlikely. Besides, only a few seborrheic received a further 3 cycles of docetaxel therapy. keratoses on the right arm became in amed, while those on the other body sites were not involved. The above features are diVerent from those of the previous reports. The mechanism of this reaction is unknown (2). Susser DISCUSSION et al. (2) reviewed the mucocutaneous reactions to chemotherIn ammation of seborrheic keratoses is a rarely described apy and mentioned in ammation of keratoses. This syndrome cutaneous reaction to chemotherapy (2) and there are only 2 may or may not recur with the re-administration of the same chemotherapeutic agent(s). Discontinuation of chemotherapy previous reports mentioning this unique skin reaction (4, 5).
SDGs
Other Subjects
betamethasone valerate; cisplatin; docetaxel; gemcitabine; aged; cancer chemotherapy; case report; eczema; female; human; inflammation; letter; leukopenia; lung lobectomy; lung non small cell cancer; priority journal; seborrheic keratosis; skin manifestation; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Inflammation; Keratosis, Seborrheic; Lung Neoplasms; Paclitaxel; Taxoids
Type
letter